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INTRODUCTION
In marrow transplantation from a human leukocyte
antigen (HLA) genotypically identical sibling, graft-vs.-host
disease (GVHD) can occur when the recipient has inherited
a minor histocompatibility allele not present in the donor
[1]. Minor histocompatibility antigens are endogenous poly-
morphic peptides that occupy the cleft between the  helices
of major histocompatibility complex (MHC) molecules.
With few possible exceptions [2,3], the specific loci that
encode peptides presented as minor histocompatibility anti-
gens and the classes of MHC molecules that can present the
polymorphic peptides involved in causing GVHD have not
been identiﬁed.
We have previously developed mathematical models to
evaluate disparity for minor histocompatibility antigens in
marrow transplant recipients [4–6]. The results suggested
that, in any individual, approximately seven minor histo-
compatibility loci might encode peptide antigens that can
cause GVHD. This result poses a paradox because most
individuals are HLA-heterozygous and express two different
alleles at each of the highly polymorphic loci in the MHC.
If HLA-C and HLA-DP are taken with HLA-A, HLA-B,
HLA-DR, and HLA-DQ and if hybrid HLA-DQ and
DQ pairing is considered [7–8], then most individuals have
10–14 different HLA molecules potentially capable of pre-
senting peptides as minor histocompatibility antigens.
The disparity between the estimated number of loci
encoding minor antigens that cause GVHD and the number
of MHC molecules that could present minor antigens might
be explained in two ways. Certain classes of MHC mole-
cules (e.g., HLA-C or HLA-DP) might not be able to pres-
ent any peptides as minor antigens that cause GVHD. Alter-
natively, the variety of minor histocompatibility antigens
could be constrained by the repertoire of polymorphic pep-
tides encoded by minor histocompatibility loci so that cer-
tain MHC molecules might not present any peptides that
initiate GVHD. For example, the cellular peptides
processed and presented by certain HLA molecules could be
encoded predominantly by either nonpolymorphic genes or
polymorphic genes with allele distributions that seldom
cause disparity between donor and recipient [4]. The poly-
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morphic peptides selected for presentation by certain HLA
molecules might lack the characteristics needed to initiate
an immune response resulting in GVHD. Critical helper or
cytotoxic determinants might be absent, or the tissue distri-
bution of antigen expression might not be permissive for the
development of GVHD. If any of these scenarios were cor-
rect, then certain HLA alleles should be associated with a
relatively reduced risk of GVHD, while others should be
associated with a relatively increased risk.
Associations between specific HLAs and reduced or
increased risk of GVHD have been reported previously
[9–12], but results among the different studies have been
inconsistent. In this study, we explored the relationship
between individual HLAs and the risk of acute GVHD after
allogeneic marrow transplantation from an HLA-identical
sibling. Contrary to results reported in previous studies, we
found no convincing evidence for any such associations.
MATERIALS AND METHODS
Patients
Individuals who received an allogeneic marrow trans-
plant from an HLA-identical sibling were identified from
computer records. Transplants were carried out between
1971 and 1996, and most patients received unmodiﬁed (T
cell-replete) marrow with the use of methotrexate, cyclo-
sporine, or their combination for GVHD prophylaxis.
Methods used for treatment of acute GVHD have been
described previously [13–14].
HLAs
All typing of HLA-A and B antigens was done by serol-
ogy. Typing of HLA-DR antigens was done by serology or
by DNA-based methods [15]. No additional testing was
done to extend the original clinical typing results. HLA
splits at each locus were deﬁned in a way that allowed us to
examine the largest possible number of patients in a consis-
tent manner. For example, we did not include individuals
typed as HLA-A9 without splitting HLA-A23 and A24,
since most patients had either HLA-A23 or A24 assigned
and only a small number were typed as HLA-A9 without
splitting. On the other hand, individuals typed as HLA-A68
or A69 were categorized as A28 because the proportion of
patients typed as HLA-A68 or A69 was small. The catego-
rization of HLAs and the numbers of patients with each
antigen in the study population are summarized in Table 1.
Table 1. Distribution of HLAs
HLA-A HLA-B HLA-C HLA-DR HLA-DQ
Number of Number of Number of Number of Number of
Antigen patients Antigen patients Antigen patients Antigen patients Antigen patients
1 775 7 655 1 102 1 417 1 1372
2 1357 8 566 2 114 2 685 2 716
3 714 13 116 3 326 3 502 3 1038
11 341 14 228 4 271 4 696 4 61
23 (9) 98 18 239 5 158 5 514 7 164
24 (9) 475 27 194 6 223 6 584
25 (10) 102 35 486 7 533 7 530
26 (10) 182 37 63 8 67 8 147
28 270 38 (16) 106 9 73
29 (19) 228 39 (16) 87 10 48
30 (19) 134 41 60
31 (19) 146 44 (12) 571
32 (19) 182 45 (12) 46
33 (19) 90 46 6
34 (10) 20 47 11
36 7 48 9
66 (10) 5 49 (21) 83
74 (19) 5 50 (21) 48
51 (5) 202
52 (5) 48
53 24
54 (22) 8
55 (22) 32
56 (22) 11
57 (17) 120
58 (17) 44
60 (40) 166
61 (40) 67
62 (15) 238
63 (15) 27
70 21
73 2
75 (15) 3
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Assessment of GVHD
The peak severity of GVHD after transplantation was
graded according to previously published criteria [16–17].
All grading before 1991 was done by a single individual and
all grading in 1991 and thereafter was done by another indi-
vidual [18]. In assigning GVHD grades, reviewers used
research files containing copies of pre-and posttransplant
inpatient, outpatient, and interim summaries written at
30-day intervals, biopsy reports, correspondence with
referring physicians, and autopsy reports. Medical sum-
maries included a paragraph specifically describing use of
medications for prophylaxis and treatment of GVHD and
discussing any clinical manifestations of GVHD that involve
the skin, liver, or gastrointestinal tract. These summaries
were reviewed and approved by the attending physician.
Also included in the research chart are daily flow sheets
abstracted from the original medical records summarizing
the percent of body surface involved with rash, the volume
of diarrhea, and the presence or absence of abdominal pain
or stool blood. Flow sheets are annotated with descriptions
of rash and biopsy results. Flow sheets also summarize
immunosuppressive medications and selected laboratory val-
ues, including the serum bilirubin concentration.
Statistics
Patients who died or relapsed before day 50 without
grades II–IV GVHD were excluded from analysis because
they remained at risk of GVHD when they died. By this cri-
terion between 9.7 and 11.3% of patients were excluded
from consideration, depending on the HLA locus under
evaluation. For each HLA-A, B, C, DR, or DQ locus,
patients were grouped according to the presence of each
antigen and the presence or absence of grades II–IV acute
GVHD. A stratiﬁed 2 statistic [19] was calculated for the
resulting n  2 table, where n is the number of HLAs con-
sidered. Stratiﬁcation was based on the two reviewers who
graded the severity of GVHD. This statistic provides a
global assessment of the null hypothesis that the risk of
GVHD is homogeneous across all antigens.
Since HLA-heterozygous patients contribute to two
rows in the table, one row for each antigen, the test statistic
for each locus did not follow a 2 distribution with n – 1
degrees of freedom, and the complicated dependent struc-
ture of the table did not allow the true distribution to be
identiﬁed. A permutation test was therefore used to estimate
the p value associated with the observed value of the test sta-
tistic. For this purpose, 5000 independent permutations
were generated by randomly redistributing the cases of
GVHD among the rows of the n  2 table, keeping ﬁxed
the overall proportion of patients with GVHD and the
number of patients possessing each antigen. The value of
the test statistic was calculated for each permutation and the
p value was estimated as the proportion of permutations
having a test statistic that exceeded the observed value of the
test statistic. With 5000 permutations, the upper and lower
limits of the 99% confidence interval associated with the
estimated p value were within 0.018 of the point estimate.
When the point estimate of the p value was as low as 0.05,
the 99% confidence limits were within 0.008 of this esti-
mate, a level of precision considered to be sufﬁcient for pur-
poses of this study.
When results of the global test statistic suggested inho-
mogeneity in the incidence of grades II–IV acute GVHD
among the antigens of a speciﬁc HLA locus (e.g., p  0.10),
the data were evaluated further to identify speciﬁc antigens
that might be associated with a decreased or increased inci-
dence of GVHD. For this purpose, a series of n-stratiﬁed 2
 2 tables, one for each antigen with stratiﬁcation for the
two reviewers, was generated according to the presence or
absence of each antigen and according to the presence or
absence of grades II–IV acute GVHD, and a 2 statistic
associated with each table was calculated. Given that 2 val-
ues were generated from multiple comparisons, nominal p
values for 2  2 tables could not be used to assess statistical
signiﬁcance. A permutation test was therefore used to esti-
mate the p value associated with each 2 value, taking into
account the effect of the multiple comparisons. For this pur-
pose, the p value associated with the antigen possessing the
largest observed 2 value was estimated as the proportion of
5000 permutations for which the largest 2 value exceeded
the largest observed 2 value, and the p value associated with
the antigen possessing the nth largest observed 2 value was
estimated as the proportion of permutations for which the
nth largest 2 value exceeded the nth largest observed value.
RESULTS
Heterogeneity in risk of GVHD among HLAs categorized by
locus
Before examining associations between individual HLAs
and risk of GVHD, we tested for global heterogeneity in risk
of GVHD among all antigens at each locus taken together.
The analysis was stratified according to the reviewer who
graded the GVHD because of signiﬁcant differences in the
distribution of grades between the two reviewers (Table 2)
[18]. By permutation tests, we found statistically signiﬁcant
evidence of heterogeneity in risk of GVHD among patients
categorized according to different HLA-DQ antigens (p 
0.05) and suggestive evidence for heterogeneity in the risk of
GVHD among patients categorized according to different
HLA-B antigens (p  0.09) (Table 3).
Heterogeneity in risk of GVHD among patients with
different HLA-DQ antigens
The evidence suggesting heterogeneity in risk of
GVHD among patients categorized according to different
Table 2. Heterogeneity in risk for grades II–IV GVHD among patients
graded by different reviewersa
GVHD Number of patients
grade Reviewer A (%) Reviewer B (%)
0 860 (42) 155 (23)
I 304 (15) 56 (8)
II 406 (20) 275 (41)
III 358 (18) 141 (21)
IV 102 (5) 48 (7)
Total 2030 675
aData include only the populations tested for associations between HLA-DQ or
HLA-B antigens and risk for GVHD.
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HLA-DQ antigens as a whole prompted us to examine asso-
ciations between risk of GVHD and individual HLA-DQ
antigens. This analysis was also stratified according to the
reviewer who graded the GVHD because of signiﬁcant dif-
ferences in the distribution of grades between the two
reviewers (Table 2). In this analysis, HLA-DQ7 was associ-
ated with an increased risk of grades II–IV acute GVHD
and the unadjusted p value for this association was nominally
signiﬁcant ( p  0.014) (Table 4). With corrections for mul-
tiple comparisons by a permutation test using the maximal
2 value as the test statistic, however, the association
between HLA-DQ7 and an increased risk of GVHD was
not statistically signiﬁcant ( p  0.22).
Heterogeneity in risk of GVHD among patients with
different HLA-B antigens
The evidence suggesting heterogeneity in risk of
GVHD among patients categorized according to different
HLA-B antigens as a whole prompted us to examine associ-
ations between risk of GVHD and individual HLA-B anti-
gens. Only four HLA-B antigens showed nominally signiﬁ-
cant p values in testing contingency tables, correlating the
presence or absence of the antigen with the presence or
absence of grades II–IV acute GVHD (Table 5). HLA-B49,
B35, and B41 were associated with a reduced risk of
GVHD, whereas HLA-B27 was associated with an
increased risk of GVHD. Among these, HLA-B35 showed
the strongest association as measured by the lowest p value.
With corrections for multiple comparisons by a permutation
test using the maximal 2 value as the test statistic, the asso-
ciation between HLA-B35 and a reduced risk of GVHD was
not statistically signiﬁcant (p  0.15). Adjusted p values for
all other antigens were necessarily 	0.15 and, for this rea-
son, were not computed.
DISCUSSION
Four previous studies have tested associations between
HLA antigens and risk of GVHD after marrow transplan-
tation from an HLA-identical sibling. Storb et al. [9] found
heterogeneity in the risk of grades I–IV acute GVHD
among 130 patients with aplastic anemia with global cate-
gorization according to HLA-B antigens, but not with cate-
gorization according to HLA-A antigens. In their analyses,
HLA-B8 and possibly HLA-B35 appeared to be associated
with a decreased risk of GVHD, whereas HLA-B18
appeared to be associated with an increased risk. In addi-
tion, HLA-A10 appeared to be associated with an increased
risk of GVHD. Bross et al. [10] found heterogeneity in risk
of grades II–IV acute GVHD among 136 patients with
global categorization according to HLA-A antigens, HLA-
B antigens, and HLA-C antigens. In their analyses, HLA-
A19 and possibly HLA-B17 appeared to be associated with
a decreased risk of acute GVHD, whereas HLA-Cw4 and
possibly HLA-A11 and HLA-B21 appeared to be associated
with an increased risk. Weisdorf et al. [11] did not test for
heterogeneity in the risk of GVHD with global categoriza-
tion according to HLA locus, but in their analysis of 469
patients, HLA-DR3 appeared to be associated with a
decreased risk of grades II–IV acute GVHD, whereas
HLA-A26 appeared to be associated with an increased risk.
Smyth et al. [12] also did not test for heterogeneity in the
risk of GVHD with global categorization according to
HLA locus, but in their analysis of 51 patients, HLA-B7
appeared to be associated with a decreased risk of grades
I–IV acute GVHD, whereas HLA-B44 appeared to be asso-
ciated with an increased risk. No statistical corrections for
multiple comparisons with different antigens were made in
most of these studies. Storb et al. [9] acknowledged this
problem and used regression models to identify antigens
associated with an unusual relative risk of GVHD. Pairs of
antigens with signiﬁcantly different relative risks were iden-
tified by using simulations to determine critical values for
the maximum standardized pairwise test statistic.
Like the previous studies reported by Storb et al. [9] and
Bross et al. [10], we found evidence suggesting global hetero-
geneity in the risk of GVHD with categorization according to
HLA-B antigens, but we did not confirm the findings of
Bross et al. [10] who indicated global heterogeneity in risk of
GVHD with categorization according to HLA-A and HLA-
C antigens. Our current results suggesting a decreased risk of
GVHD associated with HLA-B35 are concordant with ﬁnd-
ings reported by Storb et al. [9], but our results suggesting a
decreased risk of GVHD associated with HLA-B49(21) con-
flict with results reported by Bross et al. [10], showing an
increased risk of GVHD associated with HLA-B21. No other
association between speciﬁc HLA-B antigens and the risk of
GVHD was conﬁrmed or refuted in any of the ﬁve studies
reported. The inconsistency of associations between speciﬁc
HLA-B antigens and the risk of GVHD among different
studies suggests that biological links between speciﬁc HLA-B
antigens and the risk of GVHD do not actually exist. The sta-
tistically significant findings reported previously may have
been a result of multiple comparisons.
Table 4. Heterogeneity in risk for grades II–IV GVHD among patients with
different HLA-DQ antigens
Estimated 
HLA-DQ GVHD Stratified Unadjusted adjusted 
antigen incidence odds ratio p valuea p value
1 0.51 1.14 — —
2 0.49 0.88 — —
3 0.48 0.89 — —
4 0.57 0.92 — —
7 0.62 1.52 0.014 0.222
aUnadjusted p values 	0.05 are not reported.
Table 3. Heterogeneity in risk for grades II–IV GVHD among patients with
different HLAs categorized by locus
Number of patients evaluated Estimated global
HLA locus Reviewer A Reviewer B p value
A 2129 675 0.36
B 1991 675 0.09
C 596 637 0.69
DR 1629 675 0.65
DQ 1441 661 0.05
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Our current study has three notable limitations. First,
GVHD grading is imprecise because abnormalities caused
by GVHD often cannot be easily distinguished from those
caused by other complications involving the skin, liver, and
gut. In the present study, we made statistical adjustments for
systematic differences in GVHD grading between two dif-
ferent reviewers, and we used grade II severity as the thresh-
old for defining GVHD, based on the supposition that
grade I GVHD is biologically and medically insignificant.
Recategorization of the data using grade I GVHD as the
threshold did not change our overall results. We did not cat-
egorize the data with grade III GVHD as the threshold
because quantitative differences rather than qualitative dif-
ferences characterize the distinction between grades I–II
severity and grades III–IV severity. Second, despite the
inclusion of more than 2500 patients, the statistical power
for testing associations between certain HLA antigens and
the risk of GVHD was limited. On the other hand, the lack
of statistical signiﬁcance in the global tests of heterogeneity
and the risk of GVHD with categorization according to the
antigens of any single locus argues against the presence of
strong associations between individual HLAs and GVHD
risk. Third, we examined associations between the risk of
GVHD and HLA as antigens and not as alleles. Thus it
remains a possibility that increased and decreased risks of
GVHD might be reciprocally associated with certain alleles
within an antigen group.
Four general conclusions emerge from our study. First,
we found no convincing evidence to suggest that any given
HLA molecule has a detectably increased or decreased abili-
ty to present minor histocompatibility antigens that cause
GVHD. These results are consistent with the hypothesis
that the variety of minor histocompatibility antigens is not
constrained by the repertoire of polymorphic peptides col-
lectively encoded by minor histocompatibility loci. Second,
with the possible exception of HLA-DQ, the lack of hetero-
geneity among the antigens of any locus makes it impossible
to identify the classes of HLA molecules capable of present-
ing polymorphic peptides as minor histocompatibility anti-
gens that cause GVHD. Although the MHC molecules
encoded within any given locus appear to show uniform
behavior, different classes of MHC molecules could show
considerable heterogeneity in their ability to present pep-
tides that cause GVHD. If this possibility could be excluded
and if it is assumed that complex and poorly understood
immunoregulation did not obscure any possible associations
between HLAs and the risk of GVHD, then our current
results would suggest that the number of minor histocom-
patibility loci encoding peptides that can cause GVHD in
any individual, might be larger than predicted previously
[4–6]. Third, we found no evidence to suggest that any indi-
vidual HLA is in strong linkage disequilibrium with another
locus that affects the risk of GVHD. Finally, our results
demonstrate that stringent precautions must be taken to
correct for multiple comparisons in studies attempting to
deﬁne associations between HLA and disease.
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